Cargando…

Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy

BACKGROUND: COVID-19 during pregnancy is associated with adverse outcomes for both the mother and fetus. SARS-CoV-2 vaccination has significantly reduced the risk for symptomatic disease. Several studies have reported on the safety of SARS-CoV-2 vaccination during pregnancy, with no adverse effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dick, Aharon, Rosenbloom, Joshua I., Karavani, Gilad, Gutman-Ido, Einat, Lessans, Naama, Chill, Henry H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988438/ https://www.ncbi.nlm.nih.gov/pubmed/35398583 http://dx.doi.org/10.1016/j.ajogmf.2022.100637

Ejemplares similares

Safety of SARS-CoV-2 vaccination during pregnancy- obstetric outcomes from a large cohort study
por: Dick, Aharon, et al.
Publicado: (2022)

Induction of labor in twin pregnancy in patients with a previous cesarean delivery
por: Dick, Aharon, et al.
Publicado: (2023)

Artificial rupture of membranes as a mode for induction of labor in women with a previous cesarean section- a retrospective cohort study
por: Dick, Aharon, et al.
Publicado: (2022)

The association between history of retained placenta and success rate of misoprostol treatment for early pregnancy failure
por: Cohen, Adiel, et al.
Publicado: (2023)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6–14 months follow-up
por: Karavani, Gilad, et al.
Publicado: (2022)

Obstetric outcomes of young women following in-vitro fertilization: a case–control study
por: Karavani, Gilad, et al.
Publicado: (2022)

Growth pattern of uterine leiomyoma along pregnancy
por: Chill, Henry Hillel, et al.
Publicado: (2019)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
por: Shmueli, Einat Shacham, et al.
Publicado: (2022)

Symptomatic pelvic hematoma following hysterectomy: risk factors, bacterial pathogens and clinical outcome
por: Chill, Henry H., et al.
Publicado: (2020)

Communication with fertility patients during the COVID-19 pandemic- let's talk about it
por: Karavani, Gilad, et al.
Publicado: (2021)

Obstetric anal sphincter injury in adolescent mothers
por: Chill, Henry H., et al.
Publicado: (2021)

Gonadotropin releasing hormone analogue treatment of central precocious puberty is not associated with altered prevalence of polycystic ovary syndrome: a single center cohort study
por: Karavani, Gilad, et al.
Publicado: (2021)

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults
por: Zhang, Yuntao, et al.
Publicado: (2022)

The third booster vaccination dose against COVID-19: indication for circulating SARS-CoV-2 variants
por: Rahimi, Farid, et al.
Publicado: (2021)

Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
por: Deng, Jie, et al.
Publicado: (2022)

Booster effect of the third dose of SARS-CoV-2 mRNA vaccine in Japanese kidney transplant recipients
por: Kawabe, Mayuko, et al.
Publicado: (2023)

Safety of seven COVID-19 vaccine booster doses
Publicado: (2021)

COVID-19 booster doses in pregnancy and global vaccine equity
por: Kalafat, Erkan, et al.
Publicado: (2022)

The effect of SARS-CoV-2 BNT162b2 vaccine on the symptoms of women with endometriosis
por: Gilan, Adi, et al.
Publicado: (2022)

Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants
por: Seki, Yohei, et al.
Publicado: (2022)

BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
por: Hod, Tammy, et al.
Publicado: (2022)

IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers
por: Rasheed, Waleed S., et al.
Publicado: (2023)

Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
por: Mengesha, Bethlehem, et al.
Publicado: (2022)

Sudden Sensorineural Hearing Loss after Third Dose Booster of COVID-19 Vaccine Administration
por: Zoccali, Federica, et al.
Publicado: (2022)

Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease
por: Cossiga, Valentina, et al.
Publicado: (2023)

Safety and immunogenicity of booster dose in patients with chronic liver disease
por: Cossiga, V., et al.
Publicado: (2023)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Safety of COVID-19 booster dose: is the juice worth the squeeze?
por: Madhi, Shabir A, et al.
Publicado: (2023)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review
por: Al Hajji, Youssra, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
por: Gareayaghi, Nesrin, et al.
Publicado: (2022)

A sigh of relief: vaccine-associated hypermetabolic lymphadenopathy following the third COVID-19 vaccine dose is short in duration and uncommonly interferes with the interpretation of [(18)F]FDG PET-CT studies performed in oncologic patients
por: Cohen, Dan, et al.
Publicado: (2021)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Safety and Adverse Events Among Long-term Care Residents Receiving a Third COVID-19 mRNA Vaccine Booster Dose in Quebec
por: Zhang, Xi Sophie, et al.
Publicado: (2022)

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers
por: Hussein, Khetam, et al.
Publicado: (2022)

A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mo9bq7sake1sdk94etri0patcu